| 05.10.22 | Emergent destroyed 400M COVID shots; Pfizer buys Biohaven for $11.6B; Anthem closes Integra deal

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

2 jahre vor

Html
Text

This week's sponsor is Canaccord Genuity LLC.

Today's Rundown

The top 10 highest paid biopharma R&D executives in 2021 Emergent destroyed up to 400M COVID-19 vaccines, far more than previously known: report Anthem closes acquisition of Integra Managed Care FDA clears its first in vitro test for the early Alzheimer’s detection Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray Pfizer buys migraine partner Biohaven for $11.6B, betting on CGRP drugs in grand return to neuroscience Senators seek to reauthorize mental health reforms, grants in latest bid to improve access Triple threat: Varian, HP and Adaptiiv form 3D printing pact to improve radiation therapy Rallybio wades into Sanofi storeroom for $3M rare disease deal Bayer's pharma business feels the pain from Xarelto generics in China GoodRx stock tumbles as 2022 revenue expected to take a hit from grocery chain prescription dispute BlueWind Medical breezes into $64M series B for overactive bladder neurostim device

Featured Story

The top 10 highest paid biopharma R&D executives in 2021

By Max Bayer

The top 10 list of the highest-paid biopharma R&D execs looks a little bit different in 2021 than the year before after a number of pendulum swings in pay. And the new top 2 earners have since left their top research posts for CEO roles elsewhere.

This week's sponsor is Perkin Elmer.

Emergent destroyed up to 400M COVID-19 vaccines, far more than previously known: report

By Zoey Becker

Emergent BioSolutions' COVID-19 vaccine manufacturing woes were well documented in 2021, but a new congressional probe found that the company's problems went much further than realized.

Anthem closes acquisition of Integra Managed Care

By Paige Minemyer

The insurer announced plans to acquire Integra, a long-term care plan, in November.

FDA clears its first in vitro test for the early Alzheimer’s detection

By Conor Hale

The FDA said the Lumipulse test developed by Fujirebio Diagnostics could allow some patients to skip PET brain scans for finding amyloid plaques.

Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray

By Max Bayer

Biotech deal making has received a much-needed shot in the arm as Pfizer coughed up $11.6 billion for Biohaven, including its late-stage migraine nasal spray.

Pfizer buys migraine partner Biohaven for $11.6B, betting on CGRP drugs in grand return to neuroscience

By Angus Liu

Pfizer is channeling its large COVID-19 windfall into dealmaking, buying Biohaven's CGRP migraine portfolio for $11.6 billion six months after partnering up on ex-U.S. markets for marketed med Nurtec.

Senators seek to reauthorize mental health reforms, grants in latest bid to improve access

By Robert King

A bipartisan duo of senators introduced legislation to reauthorize several key mental health programs, the latest reform Congress is exploring to improve access.

Triple threat: Varian, HP and Adaptiiv form 3D printing pact to improve radiation therapy

By Andrea Park

As any engineer can attest, the triangle is the strongest shape, and Varian Medical Systems, Adaptiiv Medical Technologies and HP have formed one of their own to take on the daunting task of improving radiation therapy for cancer.

Rallybio wades into Sanofi storeroom for $3M rare disease deal

By Annalee Armstrong

Rallybio is making room for a rare disease candidate from Sanofi’s stockroom with a small $3 million upfront cash payment. The biotech will take over development of KY1066, which will be renamed RLYB331, for severe anemia and iron overload in patients who have diseases such as beta thalassemia and a certain type of myelodysplastic syndrome.

Bayer's pharma business feels the pain from Xarelto generics in China

By Kevin Dunleavy

A win in patent court in Europe last October was a pleasant surprise for Bayer, giving its heart drug Xarelto an additional two years of exclusivity—all the way to 2026. But the generics ship already has sailed for Xarelto in China and its effects are telling.

GoodRx stock tumbles as 2022 revenue expected to take a hit from grocery chain prescription dispute

By Heather Landi

Drug discount company GoodRx expects its 2022 revenue to take a hit due to recent actions by one grocery store chain that stopped accepting discounts for certain drugs.

BlueWind Medical breezes into $64M series B for overactive bladder neurostim device

By Andrea Park

An Israeli startup developing a neuromodulation device to treat urgency urinary incontinence certainly has the wind at its back these days.

Webinar: Breaking Down Research Data Silos for Accelerated Innovation

Thursday, May 19, 2022 | 2pm ET / 11am PT

Within pharma organizations, research data is often underleveraged, siloed, and disorganized—especially imaging data. This adds to timelines, hinders AI development, and prevents internal collaborations. How can pharma address these data challenges? Register Now.

Senior Editors: Ben Adams, Annalee Armstrong, Conor Hale, Heather Landi, Paige Minemyer, Eric Sagonowsky

Advertise | Contact

Editor in Chief: Tracy Staton

Managing Editor: Querida Anderson

Senior Multimedia Producer: Teresa Carey

Multimedia Producer: Caleb Hodgson

Publisher: Rebecca Willumson

Group Sales Director: Angelique Alcover

Manage Your Subscriptions

Trouble with your subscription?
Contact Support

This email was sent to [email protected] as part of the Fierce Life Sciences email list

Teilen auf

Laden...

Weitere Newsletter von Fiercebiotech.com

Laden...

PM Tracker

Featured Story

The top 10 highest paid biopharma R&D executives in 2021

Top Stories

Emergent destroyed up to 400M COVID-19 vaccines, far more than previously known: report

Anthem closes acquisition of Integra Managed Care

FDA clears its first in vitro test for the early Alzheimer’s detection

Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray

Pfizer buys migraine partner Biohaven for $11.6B, betting on CGRP drugs in grand return to neuroscience

Senators seek to reauthorize mental health reforms, grants in latest bid to improve access

Triple threat: Varian, HP and Adaptiiv form 3D printing pact to improve radiation therapy

Rallybio wades into Sanofi storeroom for $3M rare disease deal

Bayer's pharma business feels the pain from Xarelto generics in China

GoodRx stock tumbles as 2022 revenue expected to take a hit from grocery chain prescription dispute

BlueWind Medical breezes into $64M series B for overactive bladder neurostim device

| 05.10.22 | Emergent destroyed 400M COVID shots; Pfizer buys Biohaven for $11.6B; Anthem closes Integra deal

PM Tracker

Featured Story

Top Stories

Teilen auf

Weitere Newsletter von Fiercebiotech.com

Verwandte Newsletter